Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep 12;148(11):872-881.
doi: 10.1161/CIRCULATIONAHA.123.064847. Epub 2023 Aug 29.

Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study

Affiliations
Randomized Controlled Trial

Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study

Mark Hofmeyer et al. Circulation. .

Abstract

Background: Dilated cardiomyopathy (DCM) can lead to advanced disease, defined herein as necessitating a durable left ventricular assist device or a heart transplant (LVAD/HT). DCM is known to have a genetic basis, but the association of rare variant genetics with advanced DCM has not been studied.

Methods: We analyzed clinical and genetic sequence data from patients enrolled between 2016 and 2021 in the US multisite DCM Precision Medicine Study, which was a geographically diverse, multiracial, multiethnic cohort. Clinical evaluation included standardized patient interview and medical record query forms. DCM severity was classified into 3 groups: patients with advanced disease with LVAD/HT; patients with an implantable cardioverter defibrillator (ICD) only; or patients with no ICD or LVAD/HT. Rare variants in 36 DCM genes were classified as pathogenic or likely pathogenic or variants of uncertain significance. Confounding factors we considered included demographic characteristics, lifestyle factors, access to care, DCM duration, and comorbidities. Crude and adjusted associations between DCM severity and rare variant genetic findings were assessed using multinomial models with generalized logit link.

Results: Patients' mean (SD) age was 51.9 (13.6) years; 42% were of African ancestry, 56% were of European ancestry, and 44% were female. Of 1198 patients, 347 had LVAD/HT, 511 had an ICD, and 340 had no LVAD/HT or ICD. The percentage of patients with pathogenic or likely pathogenic variants was 26.2%, 15.9%, and 15.0% for those with LVAD/HT, ICD only, or neither, respectively. After controlling for sociodemographic characteristics and comorbidities, patients with DCM with LVAD/HT were more likely than those without LVAD/HT or ICD to have DCM-related pathogenic or likely pathogenic rare variants (odds ratio, 2.3 [95% CI, 1.5-3.6]). The association did not differ by ancestry. Rare variant genetic findings were similar between patients with DCM with an ICD and those without LVAD/HT or ICD.

Conclusions: Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members.

Registration: URL: https://www.

Clinicaltrials: gov; Unique identifier: NCT03037632.

Keywords: cardiomyopathy, dilated; genetics; risk.

PubMed Disclaimer

Conflict of interest statement

Disclosures None.

Figures

Figure 1.
Figure 1.
DCM Precision Medicine Study recruitment and analysis.
Figure 2.
Figure 2.. Most deleterious DCM-related rare variant by DCM severity status.
This figure presents the percent distributions of patients by their most deleterious DCM-related rare variant (P/LP, VUS only, or negative) and DCM severity status (LVAD/HT, ICD only, or neither). The percentage of patients with P/LP variants was higher for those with LVAD/HT compared with those with ICD and none (26.2%, 15.9%, and 15.0%, respectively, Ps<0.001). Abbreviations: ICD=Implantable cardioverter-defibrillator. LVAD=Left ventricular assist device. P/LP=Pathogenic/Likely pathogenic. VUS=Variant of uncertain significance.

Similar articles

Cited by

References

    1. Njoroge JN, Mangena JC, Aribeana C, Parikh VN. Emerging Genotype-Phenotype Associations in Dilated Cardiomyopathy. Curr Cardiol Rep 2022;24:1077–1084. - PubMed
    1. Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, Kaski JP, Maggioni AP, Rubis PP, Jurcut R, et al. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Fail 2021;8:95–105. - PMC - PubMed
    1. Klauke B, Gaertner-Rommel A, Schulz U, Kassner A, Zu Knyphausen E, Laser T, Kececioglu D, Paluszkiewicz L, Blanz U, Sandica E, et al. High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2-gene mutation. PLoS One 2017;12:e0189489. - PMC - PubMed
    1. Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, Padron-Barthe L, Grillo JJ, Vilches C, Segovia J, et al. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant 2016;35:625–35. - PubMed
    1. Martins E, Sousa A, Canedo P, Leite S, Pinto R, Campelo M, Amorim S, Moura B, Lopes JM, Machado JC, et al. Genetic variants identified by target next-generation sequencing in heart transplant patients with dilated cardiomyopathy. Rev Port Cardiol (Engl Ed) 2019;38:441–447. - PubMed

Publication types

Associated data